HPR56 Exploring If a Price Premium Is Requested for Cancer Drugs That Seek Reimbursement on State-Subsidised Schemes in Ireland: An Analysis of Drugs That Have Undergone a Full HTA by the NCPE in Ireland Between 2019 and 2023
Abstract
Authors
E Johnston H Condell M Harbourne A Ahmad L. Trela-Larsen C Walsh